TI
FHTX icon

Trexquant Investment’s Foghorn Therapeutics FHTX Stock Holding History

Trexquant Investment’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,111
Closed -$144K – 2000
2026
Q1 		$144K Buy
+30,111
New +$165K ﹤0.01% 1687
2025
Q4 		– Sell
-22,025
Closed -$108K – 1692
2025
Q3 		$108K Buy
+22,025
New +$117K ﹤0.01% 1535
2025
Q2 		– Sell
-35,585
Closed -$130K – 1639
2025
Q1 		$130K Sell
35,585
-26,013
-42% -$119K ﹤0.01% 1492
2024
Q4 		$291K Buy
61,598
+994
+2% +$7.24K ﹤0.01% 1411
2024
Q3 		$564K Buy
+60,604
New +$439K 0.01% 1220
2023
Q2 		– Sell
-14,283
Closed -$88.6K – 1543
2023
Q1 		$88.6K Sell
14,283
-21,973
-61% -$144K ﹤0.01% 1380
2022
Q4 		$231K Buy
36,256
+14,059
+63% +$106K 0.01% 1192
2022
Q3 		$190K Buy
+22,197
New +$286K 0.01% 1203

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Trexquant Investment's FHTX Position: Q2 2026 in Review

Trexquant Investment sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 30,111 shares — an estimated $144K sold.

Trexquant Investment first reported a position in FHTX in Q3 2022 and held it in 8 quarters. The position peaked at $564K in Q3 2024. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Trexquant Investment reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Trexquant Investment sold 30,111 Foghorn Therapeutics shares in Q2 2026, an estimated $144K.
  • Trexquant Investment first reported a position in Foghorn Therapeutics in Q3 2022 and held it in 8 quarters.
  • Trexquant Investment's Foghorn Therapeutics position peaked at $564K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.